Q-omics provides the consensus-scored TRAPPC9 profile across patient tissues and cancer cell-line models. TRAPPC9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC9 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TRAPPC9 protein abundance shows 24,857 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where TRAPPC9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC9 survival associations across molecular data types. TRAPPC9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC9 RNA expression–survival associations across cancer types. High TRAPPC9 expression shows unfavorable associations in LUSC, BLCA, LUAD and DLBC, but favorable associations in KIRC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRAPPC9 RNA expression.
This table summarizes TRAPPC9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAPPC9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC9 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, BRCA, LUAD and STAD. The COAD box plot shows higher TRAPPC9 RNA expression in tumor versus normal tissue (log2 FC = +0.888, t-test p < 0.001).
This table shows molecular features associated with TRAPPC9 in patient tissues and cancer cell lines. In patient samples, TRAPPC9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
